Health & Medicine

Newsom Promotes Affordable Insulin, but California's Generic Label Off to a Slow Start

25 sec read10 views0 listens

California has launched its own low-cost insulin brand, CalRx, priced at $55 per pack, aiming to make the drug more affordable and accessible for uninsured or underinsured patients. Despite initial distribution challenges, the initiative seeks to disrupt the pharmaceutical industry by increasing generic drug manufacturing and availability, addressing high prescription drug costs in the U.S.

Read the full article at KFF Health News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Health & Medicine2 days ago29 sec read

STAT+: Pharmalittle: We're reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more

Regeneron Pharmaceuticals has received U.S. regulatory approval for Pasatru, a drug aimed at treating fibrodysplasia ossificans progressiva (FOP), a rare disease causing abnormal bone growth. Separately, Ultragenyx Pharmaceutical’s gene therapy Gengl...

Ali Nemati

Health & Medicine3 days ago25 sec read

STAT+: Pharmalittle: We're reading about an FDA commish nominee, mRNA cancer vaccine results, and more

President Trump is expected to nominate Heidi Overton, a key health policy advisor in his administration, as the next FDA commissioner. Additionally, a late-stage clinical trial shows that a personalized mRNA cancer vaccine, when combined with existi...

Ali Nemati

Health & Medicine4 days ago33 sec read

STAT+: Pharmalittle: We're reading about a setback for Eyepoint, a win for Amylyx, and more

Eyepoint Pharmaceuticals announced that its experimental treatment for wet age-related macular degeneration failed to meet primary goals in a Phase 3 trial, likely delaying regulatory approval and causing stock prices to drop. This setback highlights...

Ali Nemati